POEMs

Patient-Oriented Evidence That Matters

Medications Ineffective to Prevent Cognitive Decline or Dementia

 

Am Fam Physician. 2018 Aug 15;98(4):248-249.

Clinical Question

Are there any medications that can prevent or delay cognitive decline, cognitive impairment, or dementia?

Bottom Line

None of the medications in this systematic review prevented or delayed cognitive decline, cognitive impairment, or dementia. (Level of Evidence = 1a–)

Synopsis

These researchers searched four databases, including the Cochrane Library, to identify randomized and nonrandomized controlled trials in English that enrolled adults without dementia. They also searched reference lists of previous studies and included a previous report that evaluated interventions to prevent cognitive decline. Two reviewers evaluated the quality of the studies, and one reviewer extracted the data from the studies, which were checked by another reviewer. This wide-ranging review identified three studies of acetylcholinesterase inhibitors, although most of the impact was from a single study of donepezil (Aricept) in 512 patients with preexisting cognitive deficit. After three years, active treatment did not affect the progression to Alzheimer disease, nor did it affect any cognitive test result as compared with placebo. Other treatments were also ineffective, including antihypertensives, diabetes medication, lipid-lowering medication, nonsteroidal anti-inflammatory drugs, and testosterone. Estrogen alone or with progestin increased the risk of dementia in one low-quality trial. High-dose raloxifene (Evista), but not the usual dosage of 60 mg daily, decreased the likelihood of developing mild cognitive impairment, but not dementia, in a single study (low-quality evidence).

Study design: Meta-analysis (randomized controlled trials)

Funding source: Government

Setting: Various (meta-analysis)

Reference: Fink HA, Jutkowitz E, McCarten R, et al. Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review. Ann Intern Med. 2018;168(1):39–51.

POEMs (patient-oriented evidence that matters) are provided by EssentialEvidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see https://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

This series is coordinated by Sumi Sexton, MD, Editor-in-Chief.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.

 

 

Want to use this article elsewhere? Get Permissions

CME Quiz

More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Nov 15, 2018

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article